Welcome to our dedicated page for ProtoKinetix SEC filings (Ticker: PKTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ProtoKinetix, Incorporated filings document the regulatory record for a Nevada clinical-stage biomedical company developing AAGP®/PKX-001 applications. Recent Form 8-K and 8-K/A reports cover Regulation FD stockholder updates, leadership and board changes, and amendments to previously furnished company communications.
Proxy and consent-solicitation materials describe stockholder approval of an amendment to the articles of incorporation increasing authorized common shares. The filing record also includes Form 12b-25 notices related to annual-report timing and disclosures on the company’s common-stock authorization, governance actions, and public-company reporting status.
ProtoKinetix, Incorporated received stockholder approval by written consent to amend its Articles of Incorporation to increase the total number of authorized common shares from 500,000,000 to 600,000,000. The amendment became effective after sufficient consents were received by 5:00 p.m. Eastern Time on October 6, 2025.
As of the September 5, 2025 record date, there were 389,080,152 shares of common stock outstanding and entitled to 389,080,152 votes, and stockholders holding 57.1% of the outstanding common shares consented to the action.
ProtoKinetix, Inc. filed a Form D claiming Regulation D exemptions (Rule 506(b) and Securities Act Section 4(a)(5)) for an equity offering with a total target amount of $100,000. The issuer reports $5,000 sold to date and $95,000 remaining, with one investor already participating and a stated minimum investment of $0. The offering is not intended to last more than one year and is not tied to any business combination. The filing lists key officers: Clarence Smith identified as President and CEO, Michael Guzzetta as CFO (and signer), and Edward McDonough as a director. The issuer's principal place of business is 109 W. Main St., Dalton, Ohio 44618. The filing reports no sales commissions or finders' fees and indicates no proceeds will be paid to named executives or directors.
ProtoKinetix, Inc. filed a Definitive Proxy Statement (Form DEF 14A) identifying key corporate actors and major shareholders while including signature and consent language. Clarence E. Smith is listed as President and Director signing the document. The filing discloses a large individual holding of 27,700,776 shares owned directly by Alexandra Smith and a joint holding of 23,458,709 shares owned directly by John and Edith Smith, with principal addresses provided. The document includes checklist items for filing fees and references fiscal year periods ending December 31, 2024, March 31, 2025, and June 30, 2025 along with their SEC filing dates. The text also shows a voting response option marked as "CONSENT WITHHELD (\u201cAGAINST\u201d)".